Abstract
SummaryIn 2010, eight Austrian medical societies proposed a joint position statement on the management of metabolic lipid disorders for the prevention of vascular complications. An updated and extended version of these recommendations according to the current literature is presented, referring to the primary and secondary prevention of vascular complications in adults, taking into consideration the guidelines of other societies. The “Austrian Lipid Consensus – 2016 update” provides guidance for individualized risk stratification and respective therapeutic targets, and discusses the evidence for reducing vascular endpoints with available lipid-lowering therapies. Furthermore, specific management in key patient groups is outlined, including subjects presenting with coronary, cerebrovascular, and/or peripheral atherosclerosis; diabetes mellitus and/or metabolic syndrome; nephropathy; and familial hypercholesterolemia.
Highlights
Disorders of blood lipid metabolism are well-established risk factors for atherosclerosis
RF risk factor/marker, Low-density lipoprotein cholesterol (LDL-C) low-density lipoprotein cholesterol aSCORE (Systematic COronary Risk Evaluation) is based on data from 12 European cohort studies with a total of more than 205,000 participants and gives information about the risk of cardiovascular mortality, calculated for 10 years or until age 60 [13] bThe Framingham tables are based on data from the Framingham Heart Study with approximately 5,000 participants and provide an estimation of absolute coronary heart disease (CHD)
A high high-density lipoprotein cholesterol (HDL-C) value is seen as a “negative” risk factor: in risk assessment, one positive risk factor should be subtracted in the presence of HDL-C values beyond 60 mg/dl
Summary
Disorders of blood lipid metabolism are well-established risk factors for atherosclerosis. The “Austrian Lipid Consensus – 2016 update” is geared to the recommendations of the United States National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III; 2001, 2004) [6, 7], the recent European guidelines for the management of dyslipidemia (2011) [8] and the prevention of cardiovascular disorders (CVD; 2012) [9], and the recommendations of the European Atherosclerosis Society (EAS; 2014) [10], as well as the International Familial Hypercholesterolemia (FH) Foundation Consensus Group (2015) [11], in each case incorporating further recent study data. The recommendations refer to lipid management in the framework of primary and secondary prevention in patients from the age of 18 years
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.